BioGlyco supplement products (including BioGlyco Flow, BioGlyco Capsules, and BioGlyco Blood) are not affiliated with CD BioGlyco.
CD BioGlyco does not manufacture, distribute, or provide after-sales support for these consumer products. For any product-related questions, please contact the original seller directly.
This advanced engineered formulation features octreotide peptide functionalized dihydroartemisinin liposomes (OCT-modified dihydroartemisinin liposomes). The structural matrix incorporates the hydrophobic sesquiterpene lactone compound dihydroartemisinin directly within the lipophilic hydrocarbon tail domains of a phospholipid bilayer shell, whose exterior surface is functionalized with specific octreotide (OCT) somatostatin receptor-targeting peptides linked via polymer-lipid anchors. This precise modification alters the interfacial water structure and introduces a dense target-mimetic macromolecular array, completely preventing physical vesicle aggregation while controlling the passive leakage or phase separation of the volatile sesquiterpene core cargo.
Source
Custom synthesis
Functional Group
Octreotide (OCT); Dihydroartemisinin
Form
Solid or powder
Purity
≥95%
Impurities
No visible impurities to the naked eye.
Identity
HPLC/MS/NMR
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.